The kind of “treatment” I like to see. Education and work on family dynamics…we can all benefit from learning how to interact better with our fellow human beings…starting at home with our kids makes the most sense, doesn’t it? Don’t imagine it’s just poor families that would benefit from parents learning how to better interact with their kids.
Parents developing nurturing skills on pilot course report big drop in behavioural problems among their children
As a parent it can sometimes feel as if you are drowning in conflicting information about your child’s requirements; what they should be eating, what they should be learning. But there is one area where we might all like a little more help; how to improve parenting skills that can be of long-term benefit to their mental health.
One in 10 children in the UK suffers from a diagnosable mental health disorder, and mental health issues for young people are an increasingly urgent concern. Now a pilot project in Southwark, south London, has found that teaching parents skills and techniques to better care for their children is having impressive consequences. The Empowering Parents, Empowering Communities course offers training in parenting, then teaches the mothers and fathers how to pass on what they have learnt. The results, for families in one of the most deprived boroughs in the country – where children have an above average likelihood of mental health problems – are being described as “inspirational”. read more
And the pHARMa phenomena of testing drugs abroad effects our most vulnerable citizens too. Our children:
There is no evidence to indicate that children have been the beneficiaries of the Pediatric Exclusivity Provision of FDAMA (enacted in 1998): there is evidence that pharmaceutical companies have increased their profits from the legislation by at least $14 billion.
The Ethics Of Overseas Pediatric Clinical Trials — Pharmalot
A new study in Pediatrics finds more pediatric trials are going overseas – 65 percent conducted under the pediatric exclusivity provision, which offers drugmakers six months of patent extension for running safety and efficacy studies – used overseas sites. More than one-third, or 38 percent, enrolled patients in a developing country, including one-third of trials testing infectious disease, cardiovascular and allergy and immunology meds. And 11 per cent only used sites outside the US (here is the abstract).